Table 3 C_max, IC₁₅, IC₅₀ and percent reduction values obtained from intestinal toxicity assays.

From: Drug-induced gastrointestinal toxicity and barrier integrity: cytoskeleton-mediated impairment in a clinically relevant human intestinal epithelium model

Drug	Clinical C_max (μM)	IC₁₅ (μM)				IC₅₀ (μM)				Reduction (%)
Drug	Clinical C_max (μM)	hIEC TEER	Caco-2 TEER	hIEC ATP	Caco-2 ATP	hIEC TEER	Caco-2 TEER	hIEC ATP	Caco-2 ATP	hIEC TEER	Caco-2 TEER	hIEC ATP	Caco-2 ATP
Paclitaxel	5.1	2.71	7.04	8.01	69.00	15.33	39.91	45.41	391.00	89.51	76.32	60.91	19.38
Docetaxel	5.1	4.36	19.25	88.94	291.18	24.69	109.10	504.00	1650.00	91.28	50.38	10.69	1.71
Capecitabine	13.7	5.74	10.27	62.59	>100 μм	32.52	58.21	354.70	>100 μм	79.92	70.45	18.49	−10.35
Cyclophosphamide	122.0	7.40	22.84	40.50	>100 μм	41.91	129.40	229.50	>100 μм	67.94	44.51	29.32	−15.13
Cisplatin	14.8	30.49	44.45	2.62	7.10	172.80	251.90	14.84	40.26	36.84	31.31	78.90	84.85
5-FU	34.1	19.31	17.60	87.78	74.47	109.40	99.74	497.40	422.00	65.48	78.64	22.64	24.14
Doxorubicin	7.6	1.99	3.08	0.28	7.42	11.28	17.48	1.61	42.04	95.35	94.75	76.28	58.92
Gefitinib	0.5	3.80	2.41	5.81	2.24	21.51	13.68	32.95	12.72	90.44	98.16	75.25	82.42
Crizotinib	1.0	4.81	4.64	5.70	3.78	27.25	26.31	32.32	21.41	88.04	98.27	82.94	86.50
Sunitinib	0.3	3.68	7.70	2.25	6.24	20.87	43.61	12.77	35.35	96.79	91.17	80.96	80.57
Sorafenib	6.5	3.36	3.77	3.26	19.82	19.05	21.38	19.32	112.30	87.72	93.32	75.98	43.81
Lapatinib	4.2	5.44	2.98	3.48	3.64	30.82	16.89	19.73	20.63	80.26	93.56	79.81	79.31
Ibuprofen	145.0	>100 μм*	>100 μм	>100 μм	59.49	>100 μм	>100 μм	>100 μм	337.10	−8.14	−23.28	1.75	24.28
Diclofenac	5.0	43.52	1018.24	>100 μм	110.47	246.60	5,770.00	>100 μм	626.00	23.83	0.99	3.31	16.63
Naproxen	313.0	7.90	37.01	177.71	42.25	44.75	209.70	1,007.00	239.40	47.84	54.68	14.01	34.81
Ketoprofen	10.8	14.11	25.50	150.74	30.46	79.98	144.50	854.20	172.60	49.84	59.11	17.00	38.82
Ketorolac	11.0	134.29	156.05	150.74	34.82	761.00	884.30	854.20	197.30	10.60	14.63	17.00	30.03

C_max values (µM) were obtained from referenced sources. IC₁₅, IC₅₀ and percent reduction metrics were measured using TEER and ATP cell viability assays in hIEC and Caco-2 intestinal epithelial models. IC values reported as ‘>100 µM’ indicate right-censored data where no cytotoxicity or barrier disruption was detected at the highest tested concentration (100 µM). These cases were considered nontoxic within the assay range and were excluded from dose–response curve fitting.
*IC₁₅ and IC₅₀ values reported as ‘>100 µM’ indicate right-censored data where no cytotoxicity or barrier disruption was detected at the highest tested concentration (100 µM). These cases were considered nontoxic within the assay range and were excluded from curve fitting.

Back to article page

Table 3 C_max, IC₁₅, IC₅₀ and percent reduction values obtained from intestinal toxicity assays.

Search

Quick links